HHLA2 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, studies have reported that HHLA2 in chronic myeloid leukemia cells interacts with KIR3DL3 in NK cells (inhibitory receptor for HHLA2), leading to the inhibition of NK cell cytotoxicity [20].